Drugs / Elezanumab
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02601885 | Oct 2016 → Apr 2018 | multiple sclerosis | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT02606630 | Oct → Dec 2015 | multiple sclerosis | AbbVie | Terminated | No outcome recorded |
| Phase 24 trials · 1 missed | ||||||
| Phase 2 | NCT04309474 | Nov 2020 → Apr 2024 | ischemic stroke | AbbVie | Completed | Missed primary |
| Phase 2 | NCT04295538 | Sep 2020 → Jan 2026 | spinal cord injury | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT03737812 | Feb 2019 → Jan 2021 | multiple sclerosis | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT03737851 | Dec 2018 → Aug 2021 | multiple sclerosis | AbbVie | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT04278235 Background | — | spinal cord injury | AbbVie | No longer available | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2020-10-30 | AbbVie | Regulatory AbbVie Reports Third-Quarter 2020 Financial Results abbvie.com ↗
AbbVie announced that the FDA granted Orphan Drug and Fast Track designations for elezanumab (ABT-555), an investigational treatment for patients following spinal cord injury. |
| 2020-09-28 | AbbVie | Regulatory AbbVie Receives Orphan Drug and Fast Track Designations from the U.S. Food and Drug Administration for Elezanumab, an Investigational Monoclonal Antibody RGMa Inhibitor, for the Treatment of Spinal Cord Injury abbvie.com ↗
AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug and Fast Track designations for elezanumab (ABT-555), an investigational treatment for patients following spinal cord injury. |
All press releases naming this drug 2 releases
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | elezanumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03737851 ↗ |
| Known as | ABT-555 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02606630 ↗ |
| Known as | AE12-1Y-QL | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297743 ↗ |
| Known as | PR-1432051 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297743 ↗ |
| Action | Inhibit | “binds to an inhibitor of neuronal regeneration and neutralizes the inhibitor” NCT04295538 ↗1“Repulsive guidance molecule A inhibitor” CHEMBL4297743 ↗ |
| Modality | Monoclonal antibody | “Elezanumab is a monoclonal antibody” NCT04295538 ↗ |
| Route | Intravenous | “Intravenous Infusion” NCT02601885 ↗ |
| Target | RGMA | “Repulsive guidance molecule A inhibitor” CHEMBL4297743 ↗ |